Trial Profile
A Phase II/III Study in Patients With Amyotrophic Lateral Sclerosis (ALS)
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 13 Jun 2022
Price :
$35
*
At a glance
- Drugs Mecobalamin (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Therapeutic Use
- Sponsors Eisai Co Ltd
- 27 May 2015 Results presented at the 56th Annual Meeting of the Japanese Society of Neurology2, according to an Eisai media release.
- 27 May 2015 Results presented at the 67th Annual Meeting of the American Academy of Neurology1, according to an Eisai media release.
- 27 May 2015 According to an Eisai media release, the company has submitted an NDA for mecobalamin as a treatment for amyotrophic lateral sclerosis in Japan.